Somewhat surprising outcome, IMO, and possibly a Pyrrhic victory insofar as Bayer will have a hard time getting individual EU countries to reimburse Xarelto for the ACS indication.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”